Market Intelligence, Clinical Progress, and High-Purity Reagents for Ferroptosis-Targeting Cancer Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SLC7A11 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLC7A11 Recombinant Protein Sequence Verified. High Purity (>90%). Theoretical MW Confirmed. Endotoxin Controlled (<1.0 EU/μg). Suitable for binder screening. |
View SLC7A11 Products |
| Gene Delivery | SLC7A11 Promise-ORF / Lentivirus Full-length human SLC7A11 ORF. Ideal for generating stable overexpressing cell lines to preserve 12-transmembrane native conformation. |
View SLC7A11 Products |
| Benchmark Ab | Anti-SLC7A11 Recombinant Antibody Recombinant positive control derived from benchmark clinical/preclinical sequences. Sequence verified. |
View SLC7A11 Products |
| Validator | SLC7A11 siRNA Set Target-specific siRNA pool for target knockdown verification and specificity validation in cell-based assays. |
View SLC7A11 Products |
| Related Target A | SLC3A2 (CD98hc) The covalent chaperone partner of SLC7A11. Essential for stabilizing SLC7A11 at the plasma membrane. |
View SLC3A2 Products |
| Related Target B | GPX4 (Glutathione Peroxidase 4) Downstream master regulator of ferroptosis. Synergistic target for combination therapy profiling. |
View GPX4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of 12-TM Domain | High-titer Lentiviral particles optimized for stable cell line construction, ensuring native membrane folding and functional cystine/glutamate transport. |
| Heterodimer Validation (SLC7A11/SLC3A2) | Matched target portfolio including both SLC7A11 and SLC3A2 recombinant proteins and gene vectors for co-expression/binding assays. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as functional positive controls. |
| Off-Target / False Positives | Sequence-specific siRNA validation tools included to guarantee assay knock-down specificity. |
Live SLC7A11/xCT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SLC7A11 therapeutics is intensifying, with major players shifting focus from traditional small-molecule inhibitors to targeted biologics, including monoclonal antibodies, antibody-drug conjugates (ADCs), and combination therapies targeting the ferroptosis pathway. As first-generation system xc- inhibitors (such as sulfasalazine and erastin) demonstrate limitations in potency and specificity, the next wave of R&D is targeting highly specific monoclonal antibodies and synergistic combinations with GPX4 inhibitors or immune checkpoint blockers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Preclinical consortia, Academic spin-offs | Solid Tumors (NSCLC, Glioblastoma) | Conformational binders (Requires Lentivirus-driven stable cell lines for flow cytometry) |
| Antibody-Drug Conjugate (ADC) | Biotech startups | Triple-Negative Breast Cancer (TNBC) | Internalization Assay (Requires high-purity extracellular domain antigens and stable cell lines) |
| Small Molecule Inhibitor | Established Pharma, Biotech | Resistant Cancers, Neurodegenerative diseases | Functional transport inhibition assays (Requires SLC7A11/SLC3A2 co-expressing cell lines) |